Diabetes Consult: Selecting T2D Treatments for High-Risk Patients An Interactive Decision Support Tool

Released On
December 8, 2020

Expires On
December 8, 2021

Media Type
Internet

Completion Time
15 minutes

Specialty
Endocrinology, Primary Care

Topic(s)
Diabetes

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Clinical Care Options, LLC.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc..

Credit Available

  • Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)
  • Nurses — 0.25 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is primarily intended for endocrinologists, primary care physicians, and nurses who care for patients with T2D.

Program Overview

The goal of this activity is to improve learners’ competence and performance in SGLT2 inhibitor treatment decisions for patients with T2D with and without related comorbidities.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of SGLT2-I drugs in patients with varying degrees of CV and/or renal risk
  • Consider the key clinical evidence from CVOTs with SGLT2-I drugs in management decisions for patients with T2D

Faculty

FACULTY_NAME

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Deaconess Medical Center
Boston, Massachusetts

FACULTY_NAME

Zachary T. Bloomgarden, MD, MACE

Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

FACULTY_NAME

Anne Peters, MD

Director, USC Clinical Diabetes Program
Professor of Clinical Medicine
Keck School of Medicine of USC
Los Angeles, California

FACULTY_NAME

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Orlando, Florida

FACULTY_NAME

Robert S. Zimmerman, MD

Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio

 

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Disclosures of Conflicts of Interest

Martin J. Abrahamson, MD, FACP

  • Consulting Fees: Novo Nordisk

Zachary T. Bloomgarden, MD, MACE

  • Consulting Fees: AstraZeneca, Boehringer Ingelheim, Merck, Novartis, Sanofi
  • Ownership Interest: Humana, Johnson & Johnson, Novartis

Anne Peters, MD

  • Consulting Fees: Abbott Diabetes Care, Biorad, Lilly, MannKind, Merck, Novo Nordisk, Zealand
  • Research Support: Dexcom, vTv Therapeutics
  • Ownership Interest: Livongo, Omada Health, Pendulum Therapeutics, Stability Health.

Richard E. Pratley, MD

  • Funds for Research Support: Lexicon, Ligand, Lilly, Merck, Novo Nordisk, Sanofi
  • Consulting Fees: GlaxoSmithKline, Janssen, Lilly, Merck, Novo Nordisk, and Sanofi
  • Fees for Non-CME/CE Services: Novo Nordisk

Robert S. Zimmerman, MD

  • Research Support: Bayer, Merck, Novo Nordisk
  • Fees for Non-CME/CE Services: Bayer, Merck
  • Ownership Interest: Baxter, Bristol Myers Squibb, Pfizer, and Procter

Staff

Zachary Schwartz, MSC, ELS, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Participation and Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 09, 2020, through December 08, 2021:

  1. Register online at http://www.clinicaloptions.com.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Site Viewing Requirements

  • Web browsers: Latest versions of Edge, Internet Explorer, Chrome, Firefox, and Safari
  • Mobile devices: Latest versions of Android and iOS
  • JavaScript Enabled. This website requires JavaScript to be enabled in your browser. To enable JavaScript, click here.
  • Cookie Enabled. This website requires cookies to be enabled in your browser. To enable cookies, click here.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

For CME questions please contact: skelley@clinicaloptions.com